Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Abstract: Provided is a production method of a synthetic intermediate for a heterocyclic compound having a renin inhibitory activity and useful as a prophylactic or therapeutic drug for diabetic nephropathy, hypertension and the like. A production method of a compound represented by the formula (III-1a), the formula (III-1b), the formula (III-1c) and/or the formula (III-1d); wherein each symbol is as described in DESCRIPTION, or a salt thereof, including reacting a compound represented by the formula (Ia) or (Ib): wherein each symbol is as described in DESCRIPTION, or a salt thereof with a compound represented by the formula (II): wherein each symbol is as described in DESCRIPTION, or a salt thereof, in the presence of an aluminum compound and a chiral amine compound.

Abstract: There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution. In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.

Abstract: Provided herein are functionalized pegylated cyanine compounds containing a reactive group suitable for labeling a biomolecule or pharmaceutical compositions and methods of use thereof. In one embodiment, the compounds are based on formula I shown below. In other embodiments, the compounds can be pegylated at one or more of the following locations R1, R4, R6, R9, or L.

Abstract: This invention pertains to hydroformylation catalysts containing a mixture of isomeric forms of halo-phosphorus ligands. This invention also describes a procedure for preparing isomers of certain halophosphite ligands, which contain the phosphorus atom in a macrocyclic ring.

Abstract: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or II to a patient in need thereof:

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: The present disclosure relates to acaricide, specifically to a kind of biphenyl compounds and uses thereof. The general formula I is as follows: wherein: each substituent is defined as that in the description. The compounds of the general formula I show high acaricidal activities and can be used for controlling various harmful mites.

Abstract: Provided herein are methods of making the compound of Formula I: and certain intermediates involved in such process.

Abstract: The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2,3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2,3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs.

Abstract: It relates to the use of compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, as anticancer agents and as agents for generating induced pluripotent stem cells. Compounds of formula (I?), wherein R2? is an alcoxy group, a hydrocarbon chain or a ring system, and R1, R3, and R4 are as defined herein, are dual inhibitors of histone methyltransferases and DNA methyltransferases. It also relates to the compounds of formula (I?), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein R2? is phenyl or 5- to 6-membered heteroaromatic ring, both optionally fused to another rings (i.e., compounds of formula (I)). It also relates to pharmaceutical or veterinary compositions containing compounds of formula (I).

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.

Abstract: Disclosed is a novel compound to function as a calcium-dependent chloride channel blocking agent.

Abstract: What is described is a compound of formula I wherein X is an ethene, or an unsubstituted or substituted arene or heteroarene; Y is a bond, an ethene, or an unsubstituted or substituted arene or heteroarene; Z is S or O; L is a linear or branched alkylene of 1 to 6 carbons; R1 and R2 are independently a linear or branched alkyl or alkenyl of 1 to 18 carbons; R3 and R4 are independently a linear or branched alkyl of 1 to 6 carbons; n is 0 to 6; and m, p, q, and r are independently 1-18; or a pharmaceutically acceptable salt thereof.

Abstract: A method for preparing 3-methyl-2-nitrobenzoic acid is disclosed wherein 1,3-dimethyl-2-nitrobenzene is combined with an oxidation catalyst in the presence of an oxygen source and an initiator, provided that less than 99% of the 1,3-dimethyl-2-nitrobenzene is oxidized. A method for preparing compounds of Formula 7 and Formula 11 is also disclosed wherein the method is characterized by using 3-methyl-2-nitrobenzoic acid as prepared by the method disclosed above. wherein R1 is C1-C7 alkyl, C3-C6 cycloalkyl or C4-C7 alkylcycloalkyl.

Abstract: Provided herein are methods of making the compound of Formula I: and certain intermediates involved in such process.

Abstract: The present invention relates to a process for purifying adiponitrile (ADN), wherein crude ADN is introduced into a rectification apparatus (R1). The rectification apparatus (R1) comprises a first side draw and preferably also a second side draw, the first side draw being disposed below the crude ADN introduction point and the optional second side draw being disposed above the crude ADN introduction point. The first side draw is used to draw off a gaseous stream comprising ADN while the optional second side draw is used to draw off undesired by-products such as 1-amino-2-cyanocyclopentene (ACCP) which are often generated in ADN production and consequently may be present in the crude ADN. The gaseous stream from the first side draw of (R1) is introduced into a second rectification apparatus (R2). (R2) is used to separate off ADN from remaining high boilers and any other by-products present, pure ADN being drawn off from (D2) as overhead product.

Abstract: The present invention relates to the use of a class of novel isothiazolo[4,3-b]pyridine derivatives as well as to pharmaceutical compositions comprising one or more of said isothiazolo[4,3-b]pyridine derivatives and one or more pharmaceutically acceptable excipients as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as viral diseases.

Abstract: Provided are a surface-modifying agent that enables production of a coating film that preserves transparency of a substrate while displaying high water repellency and excellent stain resistance, particularly in terms of wipeability of oil-based ink, and also an article for which the surface-modifying agent is used. The surface-modifying agent includes a triazine skeleton, a (meth)acrylate group bonded to the triazine skeleton via an urethane bond, and a perfluoropolyether chain bonded to the triazine skeleton.